Symphony Limited Q1 FY27 Earnings Call Transcript Released
Symphony Limited's Q1 FY27 earnings call transcript reveals consolidated revenue of ₹378 crore (up 8% YoY) and adjusted EBITDA of ₹53 crore (up 50% YoY). PAT stood at ₹43 crore (up 23% YoY). Bonaire USA revenue grew 35%, GSK China revenue up 43%. The company declared an interim dividend of ₹1 per share.
The announcement provides a detailed update on quarterly results and operational performance, which is significant for investors. The positive financial metrics and strategic updates warrant a medium impact.
The company reported positive year-on-year growth in revenue and EBITDA, along with a strong performance from key subsidiaries. The management's commentary suggests a positive outlook despite some headwinds.
Symphony Limited has released the transcript of its earnings conference call for the first quarter ended June 30, 2026. The call, conducted on August 4, 2026, featured the senior management team including Chairman and Managing Director Mr. Achal Bakeri, Managing Director (Corporate Affairs) Mr. Nrupesh Shah, and Chief Growth Officer Mr. Rajesh Mishra. The management discussed the company's performance, highlighting robust domestic momentum and margin discipline. Consolidated revenue for Q1 FY27 stood at ₹378 crore, an 8% year-on-year increase, with EBITDA at ₹48 crore (up 26%) and PAT at ₹40 crore. Adjusting for one-time expenditures and income, the adjusted EBITDA was ₹53 crore (up from ₹38 crore in Q1 FY26) and PAT was ₹43 crore (up from ₹35 crore), a 23% increase. Gross margin was maintained at 49.8% and EBITDA margin at 12.6% despite headwinds.
Key operational highlights included strong performance from Bonaire USA, with revenue growing by 35%, and GSK China, with revenue up by 43%. The company is strategically diversifying away from Indian summer dependency, with 'Beyond India Summer Products' (BISP) constituting approximately 48% of consolidated trailing 12-month revenue. On a standalone basis, Symphony India reported revenue of ₹241 crore, with EBITDA at ₹30 crore and PAT at ₹28 crore. The company declared an interim dividend of ₹1 per share, amounting to a total payout of approximately ₹7 crore.
During the Q&A session, management addressed concerns about rising raw material costs, indicating potential short-term margin pressure, though some costs would be passed on. The strong growth in modern trade was attributed to normalized channel inventory. The strategy for CTPL Australia is to avoid further capital allocation, focusing on optimizing existing operations. The company expects improved performance in Mexico and the USA in the upcoming summer seasons, while GSK China is expected to maintain its momentum due to its diversified sales cycle.
What to do with a filing like this
Symphony Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Symphony Limited. Read the original for the full detail.